Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent copy number variation in IPO11 and prognostic significance of importin-11 overexpression on poor survival.
Non-muscle-invasive bladder cancer (NMIBC) often has a worse prognosis following its progression to muscle-invasive bladder cancer (MIBC), despite radical cystectomy with pelvic lymph node dissection combined with chemotherapy. Therefore, the discovery of novel biomarkers for predicting the progression of this disease and of therapeutic targets for preventing it is crucial. We performed whole-exome sequencing to analyze superficial tumor tissues (Tsup) and basal tumor tissues (Tbas) from 3 MIBC patients and identified previously unreported copy number variations in IPO11 that warrants further investigation as a molecular target. In addition, we identified a significant association between the absolute copy number and mRNA expression of IPO11 and found that high importin-11 expression was correlated with poor 3-year overall survival (OS), cancer-specific survival (CSS) and cancer-free survival (CFS) compared with low expression in the BCa patients. Importin-11 overexpression was also an independent risk factor for CSS and CFS in the BCa patients. Our study has revealed that IPO11 copy number amplification contributes to its overexpression and that these changes are unfavorable prognostic factors in NMIBC. Thus, IPO11 copy number amplification and importin-11 overexpression are promising biomarkers for predicting the progression and poor prognosis of patients with NMIBC.
Department of Urology, Yantai Yuhuangding Hospital, Yantai 264000, China.|Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Junjie
J
Zhao
Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Weidong
W
Xu
Cancer Research Department, BGI-Shenzhen, Yantian District, Shenzhen, Guangdong 518083, China.
Minghui
M
He
Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Zhensheng
Z
Zhang
Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Shuxiong
S
Zeng
Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Chong
C
Ma
Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Yinghao
Y
Sun
Department of Urology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Chuanliang
C
Xu
D000368:Aged; D003131:Combined Modality Therapy; D056915:DNA Copy Number Variations; D015870:Gene Expression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000473:pathology; D009154:Mutation; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D000073336:Whole Genome Sequencing; D028961:beta Karyopherins / Q000235:genetics*
C475690:IPO11 protein, human; D028961:beta Karyopherins
IPO11; bladder cancer; prognosis; tumor progression; whole-exome sequencing
Oncotarget. 2016 Jan 19;7(3):2867-77
26672766
Science. 2014 Oct 10;346(6206):256-9
25301631
Carcinogenesis. 2013 May;34(5):1006-11
23322153
Genes Dev. 2016 Feb 15;30(4):408-20
26883360
Bioinformatics. 2011 Oct 1;27(19):2648-54
21828086
Neoplasia. 2013 Dec;15(12):1371-8
24403859
J Exp Clin Cancer Res. 2015 Dec 01;34:145
26626145
EMBO J. 2000 Oct 16;19(20):5502-13
11032817
Genome Res. 2012 Mar;22(3):568-76
22300766
Neuro Oncol. 2015 Apr;17 (4):555-65
25304134
Semin Cancer Biol. 2014 Aug;27:39-45
24954011
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
23412337
Genome Res. 2010 Sep;20(9):1297-303
20644199
Br J Cancer. 2015 Jun 9;112(12 ):1929-37
25989275
Mod Pathol. 2014 Jan;27(1):96-106
23887301
Nat Med. 2014 Oct;20(10):1199-205
25194568
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
26808342
World J Urol. 2006 Aug;24(3):296-304
16518661
Hum Mutat. 2012 Mar;33(3):467-70
22125086
Gene. 2003 Feb 13;305(1):91-100
12594045
Biochim Biophys Acta. 2011 Sep;1813(9):1593-606
21029754
Cancer. 2013 Aug 15;119(16):3034-42
23696076
Nat Genet. 2014 Mar;46(3):225-33
24487277
Bioinformatics. 2009 Jul 15;25(14):1754-60
19451168
J Natl Cancer Inst. 2016 Apr 07;108(8):null
27059373
Genome Res. 2010 Jan;20(1):68-80
19903760
Mol Carcinog. 2015 Jul;54(7):566-76
24347284
Crit Rev Eukaryot Gene Expr. 2013;23(1):1-10
23557333
Biochem J. 2015 Jun 15;468(3):353-62
26173234
Nucleic Acids Res. 2010 Sep;38(16):e164
20601685
Nature. 2011 Jul 27;476(7360):298-303
21796119
Clin Cancer Res. 2008 Feb 1;14(3):772-81
18245538